Patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis who received a novel ...

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

Patients in the treatment arms received 1 mg, 2.5 mg, 5 mg or 10 mg doses. After 52 weeks of treatment, patients taking the ...

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

This review discussed experimental mouse models used in the pre-clinical study of liver fibrosis regression, a pivotal ...

Hepatic fibrosis is the common result of injury to the liver from a variety of damaging mechanisms, and the accurate assessment of the degree of fibrosis is clinically important. For many years ...

Carisma Therapeutics Inc. (CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at the ...

To find out, Lu's group first induced liver inflammation and fibrosis in lab mice. They then treated those mice with a substance known as FDI-6 that blocks the protein produced by the FOXM1 gene.

Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics ...

Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three ...

The ELF test yielded similar prognostic effectiveness to histologically evaluated fibrosis in predicting clinical outcomes.